您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > MitoTam iodide,hydriodide
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
MitoTam iodide,hydriodide
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
MitoTam iodide,hydriodide图片
CAS NO:1634624-74-0
规格:98%
分子量:999.82
包装与价格:
包装价格(元)
100mg电议
250mg电议
500mg电议

产品介绍
MitoTam iodide, hydriodide 他莫昔芬衍生物,它是一种电子传递链 (ETC) 抑制剂,抑制衰老细胞中的线粒体膜电位变化并影响线粒体形态。MitoTam iodide, hydriodide 是一种有效的抗癌剂。MitoTam iodide, hydriodide 抑制乳腺癌细胞中呼吸复合物 (CI- respiration) 和超复合物 (SCs) 的形成。MitoTam iodide, hydriodide 可以诱导细胞凋亡 (apoptosis)。
CAS:1634624-74-0
分子式:C52H60I2NOP
分子量:999.82
纯度:98%
存储:Store at -20°C

Background:

MitoTam iodide, hydriodide is a tamoxifen derivative[1], an electron transport chain (ETC) inhibitor, spreduces mitochondrial membrane potential in senescent cells and affects mitochondrial morphology[2].MitoTam iodide, hydriodide is an effective anticancer agent, suppresses respiratory complexes (CI-respiration) and disrupts respiratory supercomplexes (SCs) formation in breast cancer cells[1][2]. MitoTam iodide, hydriodide causes apoptosis[2].


MitoTam (0.5 μM-56 μM; 24 hours) kills breast cancer cell Lines and nonmalignant cells with an IC50 range from 0.65 μM to 55.9 μM[1].MitoTam (2.5 μM; 2-24 hours) results in stronger activation of the apoptotic pathway in MCF7 Her2high cells compared with mock MCF7 cells[1].MitoTam (0.05 μM-1 μM; 3 days) causes a concentration-dependent induction of apoptosis in breast cancer cells, while there was no effect for non-malignant breast epithelial cells[2]. Cell Viability Assay[1] Cell Line: Breast Cancer Cell Lines: BT474, MCF7, MCF7 Her2high, MCF7 Her2low, MDA-MB-231, MDA-MB-436, MDA-MB-453, SK-BR-3, T47D; NeuTL cells; Nonmalignant Cells: A014578, H9c2 cells


MitoTam (intraperitoneal injection; 2 μg/g; once a week; 4 weeks) decreases β-gal staining of lungs from MitoTam-treated mice, accompaning by a inhibition in the expression of senescence markers p16Ink4a, p21waf1 and PAI comparing control mice [2].MitoTam (intraperitoneal injection; 0.54 μmol/mouse; twice a week; 2 weeks) inhibits growth of syngeneic tumors by 80%[1].MitoTam (intraperitoneal injection; 0.25 μmol/mouse; twice a week; 2 weeks) slows down the growth of MCF7 mock tumors and stops tumor progression after two doses; suppresses Her2high carcinomas decreased threefold from the original size with complete disappearance[1]. Animal Model: 18-month-old or 2-month-old FVB/N mice[1]


[1]. Rohlenova K, et al. Selective Disruption of Respiratory Supercomplexes as a New Strategy to Suppress Her2highBreast Cancer. Antioxid Redox Signal. 2017 Jan 10;26(2):84-103. [2]. Hubackova S, et al. Selective elimination of senescent cells by mitochondrial targeting is regulated by ANT2. Cell Death Differ. 2019 Jan;26(2):276-290.